Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. SERA
SERA logo

SERA Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Sera Prognostics Inc (SERA) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
2.180
1 Day change
1.87%
52 Week Range
4.090
Analysis Updated At
2026/04/10
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

Sera Prognostics Inc (SERA) is not a good buy for a beginner investor with a long-term strategy at this time. The lack of positive catalysts, poor financial performance, insider selling, and no Intellectia Proprietary Trading Signals suggest that the stock does not present a compelling investment opportunity currently.

Technical Analysis

The MACD is positive but contracting, RSI is neutral at 50.525, and moving averages are converging, indicating no strong trend. Key support and resistance levels are pivot: 2.083, R1: 2.287, S1: 1.879, R2: 2.413, S2: 1.753. Overall, the technical indicators do not suggest a strong buy signal.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
5
Buy
9

Positive Catalysts

  • NULL identified. No recent news or significant positive developments.

Neutral/Negative Catalysts

  • Insiders are selling heavily, with a 2019.12% increase in selling activity over the last month. Financial performance is poor, with significant YoY declines in revenue (-58.33%), net income (-8.14%), and EPS (-36.00%).

Financial Performance

In Q4 2025, revenue dropped to $10,000 (-58.33% YoY), net income dropped to -$7,881,000 (-8.14% YoY), and EPS fell to -0.16 (-36.00% YoY). Gross margin increased to -320, but this is not a positive indicator given the negative value.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No recent analyst rating or price target changes are available.

Wall Street analysts forecast SERA stock price to rise
3 Analyst Rating
Wall Street analysts forecast SERA stock price to rise
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 2.180
sliders
Low
5
Averages
5
High
5
Current: 2.180
sliders
Low
5
Averages
5
High
5
Jefferies
initiated
$5
AI Analysis
2025-12-14
Reason
Jefferies
Price Target
$5
AI Analysis
2025-12-14
initiated
Reason
Jefferies initiated coverage of Sera Prognostics with a Buy rating and $5 price target. Sera is a women's health diagnostics company developing predictive biomarker testing for pregnancy complications, the analyst tells investors in a research note. The firm says the company's flagship product PreTRM offers a simple blood test for predicting individualized risk for spontaneous preterm birth in asymptomatic pregnancies. Jefferies cites PreTRM's first to market clinical validation, "attractive" $1.6B addressable market in the U.S. and its early traction with Elevance partner and Medicaid pilot programs for the Buy rating.

People Also Watch